

biogen idec

February 4, 2011

***BY E-MAIL AND FEDERAL EXPRESS***

Commander Krista Pedley  
Director  
Office of Pharmacy Affairs  
Health Resources and Services Administration  
Department of Health and Human Services  
5600 Fishers Lane, Parklawn Building  
Mail Stop 10C-03  
Rockville, Maryland 20857

**Re: Biogen Idec (Labeler Code 59627) Re-Calculation of 340B Ceiling Prices for Q3 2005 through Q3 2007**

Dear Commander Pedley:

I am writing on behalf of Biogen Idec (“Biogen”) (labeler code 59627) to inform the Office of Pharmacy Affairs of Biogen’s intent to provide payment to Section 340B program covered entities that purchased certain products during fourth quarter 2000 through first quarter 2008 (“Restatement Period), as explained in this letter.

In January 2009, Biogen submitted to the Center for Medicare and Medicaid Services (“CMS”) revised Average Manufacturer Prices (“AMP”) and Best Price (“BP”) for certain products during third quarter 2005 through third quarter 2007. These resubmissions arose out of a comprehensive review of Biogen’s Medicaid AMP and BP calculations methodology.

In addition to the comprehensive review noted above, Biogen has also identified earlier historical quarters in which Biogen submitted corrected AMP and/or BP figures to CMS which also would have impacted the 340B ceiling prices offered to covered entities during the Restatement Period.

Biogen has recalculated the 340B ceiling prices based on these restated AMPs and BPs for the Restatement Period and the listed products in Attachment A. In some cases the recalculated ceiling prices are higher than the original ceiling prices and in some cases they are lower. Biogen intends to provide payment to those 340B covered entities that would have paid less over the applicable periods had they purchased the listed products at the recalculated ceiling prices for those products. Each of those entities will receive a check in an amount that reflects the aggregate amount over the Restatement Period for products on which they would have paid less, together with a letter explaining the reason for the payment and notification that acceptance of the

biogen idec

check will constitute full and final satisfaction of any claims related to prices charged by Biogen for the Restatement Period. Biogen has not offset any payments to the 340B covered entities in situations where the 340B covered entities paid less than the recalculated ceiling prices during the Restatement Period.

Please feel free to post this letter on the OPA website to help inform the 340B entities. If you or any of the entities have any questions regarding the refund process, I may be reached at (617) 914-4629 or via email at [Lisa.Kiniklis@biogenidec.com](mailto:Lisa.Kiniklis@biogenidec.com).

Sincerely,

Lisa Kiniklis  
Associate Director  
Government Pricing & Compliance  
Biogen Idec

Enclosures:

Attachment A: Products

**ATTACHMENT A**

| NDC           | PRODUCT NAME               |
|---------------|----------------------------|
| 59627-0001-02 | Avonex Lyo PK/4            |
| 59627-0002-03 | Avonex Liquid 30 Mcg, PK/4 |
| 59627-0021-03 | Amevive IM 15 Mg, PK/4     |
| 59627-0021-04 | Amevive IM 15 Mg, PK/1     |